Skip to content

The Influence of Pressure Pain on [11C]Diprenorphine Binding Potentials

The Influence of Pressure Pain on [11C]Diprenorphine Binding Potentials

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01546155
Enrollment
11
Registered
2012-03-07
Start date
2011-12-31
Completion date
2015-12-31
Last updated
2017-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Controls

Brief summary

Healthy volunteers aged 21 to 50 are needed for a research study investigating whether pain will alter the binding properties of (\[11C\]diprenorphine), a molecule that can be used during brain imaging. Positron Emission Tomography (PET) and functional Magnetic Resonance (fMRI) imaging will be used in this study.

Interventions

RADIATIONPET imaging

Up to a 120 minute PET scan using \[11C\]diprenorphine as the radiotracer

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy male and female adults, 21 to 50 years of age * No contraindications to fMRI and PET scanning * Within 15% of ideal body mass index (BMI)

Exclusion criteria

* Current significant medical, neurological, or psychiatric illness as assessed by the Physician Investigators * Women who are pregnant or breast feeding, have gone through menopause, and/or have irregular menstrual cycles * Claustrophobia * History of head trauma * Instability of responses to experimental pain (See Study Procedure Section Part II) * History of asthma * Use of psychotropic drugs or hormone treatments (including hormonal birth control) within one year of date of consent * History of smoking * Routine exercise in excess of one hour per day and/or three times per week * Non-fluent English speaker

Design outcomes

Primary

MeasureTime frameDescription
PET/MRI Brain Activationday oneSimultaneously collect fMRI-PET data in humans to investigate the change between bold signal evoked by pressure pain and bold signal evoked by non-painful pressure. The PET analyses generates one value per 120 minutes. This value is compared to the other 120 minute scan PET value in order to reflect the change.

Countries

United States

Participant flow

Participants by arm

ArmCount
Healthy Volunteers
The PET/fMRI scan session will last up to 120 minutes. Subjects will have 2 MR-PET scan sessions, each lasting up to 120 minutes, with a break between scan sessions. Approximately nine venous blood samples will be taken per scan session with a maximum of 48mL of blood drawn per scan session. Intermittent cuff pain, based on the previously determined Strong ratings, will be applied during one of the two scan sessions. Subjects will rate the pain they feel as a result of the cuff stimuli using the Gracely scale. The additional scan session for subjects will be performed under no pain, control conditions.
11
Total11

Withdrawals & dropouts

PeriodReasonFG000
Overall Studycould not tolerate long scan duration3

Baseline characteristics

CharacteristicHealthy Volunteers
Age, Continuous24.1 years
STANDARD_DEVIATION 2.7
Region of Enrollment
United States
11 participants
Sex: Female, Male
Female
6 Participants
Sex: Female, Male
Male
5 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 11
serious
Total, serious adverse events
0 / 11

Outcome results

Primary

PET/MRI Brain Activation

Simultaneously collect fMRI-PET data in humans to investigate the change between bold signal evoked by pressure pain and bold signal evoked by non-painful pressure. The PET analyses generates one value per 120 minutes. This value is compared to the other 120 minute scan PET value in order to reflect the change.

Time frame: day one

ArmMeasureValue (MEAN)Dispersion
Healthy ControlsPET/MRI Brain Activation0.21 percentage BOLD signal changeStandard Deviation 0.13

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026